Zydus receives approval from USFDA for Vardenafil Hydrochloride tablets and Ursodiol tablets

Zydus receives approval from USFDA for Vardenafil Hydrochloride tablets and Ursodiol tablets

Zydus Cadila has launched Vardenafil Hydrochloride Tablets (US RLD – LEVITRA Tablets), 2.5 mg, 5 mg, 10 mg and 20 mg in the US market upon receiving the final approval from the USFDA. Manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad, the medication is indicated for the treatment of erectile dysfunction. The group also received the final approval from the USFDA to market Ursodiol Tablets, 250 mg (US RLD – URSO 250® tablets) and 500 mg (US RLD – URSO Forte® tablets). It will be manufactured at the group’s formulations manufacturing facility at Baddi. It is indicated for the treatment of patients with primary biliary cirrhosis, a chronic disease in which the bile ducts in liver are slowly destroyed. The group now has 226 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.